P&G
Today the Procter & Gamble Company (NYSE:PG) announced donations totalling $10 million USD in personal health and hygiene, household products, sanitizers and financial support to help people in need, including families, elderly citizens and health professionals, enabling access to everyday essentials. As part of this effort, P&G is donating $1 million to support the International Federation of Red Cross and Red Crescent Societies’ (IFRC) COVID-19 appeal, as well as individual European Red Cross Red Crescent national societies’ efforts, to improve the lives of Europe’s vulnerable people across the continent during these challenging times.
Since the onset of the outbreak, P&G has been working with long-standing partner organizations to understand how to best support communities, relief agencies and those impacted by this global emergency. Today, we are taking three immediate actions to support urgent public needs.
Supporting vital health care services: We will donate an initial one million dollars to the IFRC and Red Cross Red Crescent National Societies to provide health care, medical supplies and hygiene education to vulnerable people across Europe.
IFRC Regional Director for Europe (ad interim), Elkhan Rahimov, said the donation would enable Red Cross and Red Crescent volunteers and staff across Europe to continue their vital and lifesaving work on the frontline of the COVID19 response.
“In these times of great emergency, this support will enable us to keep helping the most vulnerable in our society. Older people and immune compromised, those in quarantine and isolation, migrants and the homeless. We are truly appreciative of Procter and Gamble’s support,” Mr Rahimov said.
Improving lives at home with everyday essentials: Everyone at P&G is working diligently to maintain the production, distribution and availability of all our brands, not only for consumers but also for the comfort and confidence of the medical workers, emergency services and first responders who are on the frontline of the battle against COVID-19. We are also working with Red Cross and Red Crescent National Societies and local foodbanks, to deliver everyday cleaning, health and hygiene essentials to those who need it most. During these unprecedented times, our brands enable people to do the simple things – brush their teeth, wash their hair, shave, wear a clean shirt, change a baby diaper, keep homes and clothes clean – actions that can help restore a sense of normalcy and improve everyday life and wellbeing.
Providing hand and surface sanitizers: We are shifting manufacturing to help protect frontline workers. We recently started producing sanitizer in several P&G manufacturing sites in Europe, to ensure our people can continue operating safely and supporting hospitals, health authorities and relief organizations. We are building capacity to provide a minimum of 10,000 litres of hand sanitizer in 16 countries around Europe, enabling more than 3 million hand washes per week.
Loic Tassel, P&G President, Europe said, “In 30 years of working in the consumer goods industry, I have never experienced such challenging times impacting far more than businesses, but our neighbours, our communities – every facet of our lives. The P&G team is committed to doing everything possible to ensure the health and safety of all our employees, to continue to serve our consumers with essential products and services and to take meaningful action to help communities in need and those on the frontlines. Together, P&G and its organization partners are stepping up as a force for good in service to our communities.”.
We cannot predict how and when this crisis will end but we’re committed to be part of the solution. We have mobilized the full capabilities of P&G and our partners to help out in this time of need, and we will be there for our employees, consumers and communities — stepping up to be a force for good – however long it takes.
– ENDS –
Notes to the Editor
Visit https://www.pg.com/covid19 to learn how we’re stepping up to serve during the COVID-19 crisis.
About International Federation of Red Cross and Red Crescent Societies
About IFRC
IFRC is the world’s largest humanitarian network, comprising 192 National Red Cross and Red Crescent Societies working to save lives and promote dignity around the world.
www.ifrc.org - Facebook - Twitter - YouTube
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
To learn more, follow us on Twitter , LinkedIn , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
